This is a multicenter, prospective study of Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed Peripheral T-cell Lymphoma
Patients fully understand the study, voluntarily participate in and sign on the informed consent;
Diagnosed by histopathology Peripheral T-cell lymphoma;
ECOG PS score 0 or 1;
Relapsed or Refractory Peripheral T Cell Lymphoma；
NK/T-cell lymphoma;
Achieving CR or PR after induction chemotherapies without relapse;
Dysfunction of vital organs;
Serious history of autoimmune diseases and immunodeficiency, including: positive for human immunodeficiency virus (HIV) antibodies; Or other acquired or congenital immunodeficiency diseases; Or have a history of organ transplantation;
Peking University People's Hospital
Lead sponsor
Ruijin Hospital
Collaborator
Wuhan TongJi Hospital
Collaborator
West China Hospital
Collaborator